EASD

News

New diabetes and obesity studies making waves at EASD

As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.

News

Lilly fleshes out triple G data in diabetes and obesity

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

Sales & Marketing

Unpacking EASD 2024: Key themes, topics, and influencers

This September, Madrid played host to the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD).

Views & Analysis

The 'game changers' in diabetes: Novo and Lilly battle it ou...

Two diabetes drugs, Lilly and Boehringer Ingelheim’s (BI) Jardiance and Novo Nordisk’s Victoza, have shown they can go beyond lowering blood sugar, and actually save lives and cut heart attacks

News

AZ success with novel diabetes combo

First company to put GLP-1 together with SGLT2 class

News

Sanofi and Novo battle it out with diabetes combinations

New data presented at EASD in Munich

New diabetes and obesity studies making waves at EASD

Lilly fleshes out triple G data in diabetes and obesity

Unpacking EASD 2024: Key themes, topics, and influencers

The 'game changers' in diabetes: Novo and Lilly battle it ou...

AZ success with novel diabetes combo

Sanofi and Novo battle it out with diabetes combinations

Closing the global evidence gap in oncology, with Flatiron H...

Securing your ROI: Turning post-acquisition integration into...

EASD

Editor's Picks